# NWRD06 DNA Plasmid for HCC After Curative Resection.

Source: https://onco.cc/trials/nct07324304/  
OnCo record `nct07324304` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NWRD06 administered by electroporation in hepatocellular carcinoma, run by Newish Technology (Beijing) Co., Ltd., now recruiting.

## Summary

NWRD06 DNA Plasmid for HCC After Curative Resection. is a phase 2 interventional study registered as NCT07324304 by Newish Technology (Beijing) Co., Ltd., with 30 participants planned, started 2025-12-08 and due to reach its primary completion in 2028-12-31. Interventions recorded: NWRD06 administered by electroporation.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07324304
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD06 in Patients With Hepatocellular Carcinoma After Curative Resection.
- Sponsor: Newish Technology (Beijing) Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07324304: https://clinicaltrials.gov/study/NCT07324304

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct07324304.json